Curator Dashboard

Map of neural connections in mouse brain, built on an array of transgenic mice genetically engineered to target specific cell types. In addition to the connectivity data, information about the transgenic mouse lines and genetic tracers is available. Consists of high resolution 2-D projectivity image data that can be viewed side-by-side with the associated reference atlas and other reference datasets. Enables 3-D visualization and spatial/ontological search of connectivity models through a combination of manual and informatics analyses.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

High throughput screening services to identify small molecules that can be optimized as chemical probes to study the functions of genes, cells, and biochemical pathways, along with medicinal chemistry and informatics. This will lead to new ways to explore the functions of genes and signaling pathways in health and disease. The NIH Molecular Libraries Initiative NIH is designed to discover small molecules that interact with biologically important proteins and pathways and to provide open access to the bioassay and chemical data generated by its research centers. This will lead to new ways to explore the functions of genes and signaling pathways in health and disease. As these HTS Technologies were not previously available to the public sector, many investigators may not be familiar with the components and requirements of high throughput screening. A key challenge is to identify small molecules effective at modulating a given biological process or disease state. The Molecular Libraries Roadmap, through one of its components, the Molecular Libraries Probe Production Centers Network (MLPCN), offers biomedical researchers access to the large-scale screening capacity, along with medicinal chemistry and informatics necessary to identify chemical probes to study the functions of genes, cells, and biochemical pathways. This will lead to new ways to explore the functions of genes and signaling pathways in health and disease. There are two kinds of data that are available to the scientific community through a dedicated database: Chemical Compounds and Bioassay Results (NCBI). Various types of data, including informative records on substances, compound structures, and biologically active properties of small molecules are housed respectively within PubChem''''s three primary databases: PCSubstance, PCCompound, and PCBioAssay. To date, PubChem contains over 11 million substance records, details about approximately 5.5 million unique compound structures with links to bioassay descriptions, relevant literature, references, and assay data points and over 250 bioassays, a good percentage of which were contributed by the pilot phase of the MLP. The deposition will continue during the current MLPCN phase. NIH anticipates that these projects will also facilitate the development of new drugs, by providing early stage chemical compounds that will enable researchers in the public and private sectors to validate new drug targets, which could then move into the drug-development pipeline. This is particularly true for rare diseases, which may not be attractive for development by the private sector. Funding opportunities are available through the site.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Publications put out by the National Institute of Mental Health. Publications are available by topic: Disorders: * Attention Deficit Hyperactivity Disorder (ADHD) * Anxiety Disorders * Autism * Bipolar Disorder * Borderline Personality Disorder * Depression * Eating Disorders * Generalized Anxiety Disorder * Obsessive-Compulsive Disorder (OCD) * Panic Disorder * Post-Traumatic Stress Disorder * Schizophrenia * Social Phobia Populations * Older Adults * Men''s Mental Health * Women''s Mental Health * Children and Adolescents Research * Basic Research * Clinical Research and Trials * Research Funding * Mental Health Services Research Other * Coping with Traumatic Events * Genetics * HIV/AIDS * Imaging * Medications * NIMH * Prevention * Statistics * Suicide Prevention * Treatments

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Merging Two Gene Expression Studies via Cross Platform Normalization.

• Resource
• SciCrunch
• 13 years ago - by Anonymous

A long-term outpatient study designed to find out which treatments, or combinations of treatments, are most effective for treating episodes of depression and mania and for preventing recurrent episodes in people with bipolar disorder. This study has been completed. (2005) STEP-BD is evaluating all the best-practice treatment options used for bipolar disorder: mood-stabilizing medications, antidepressants, atypical antipsychotics, and psychosocial interventions - or talk therapies - including Cognitive Behavioral Therapy, Family-focused Therapy, Interpersonal and Social Rhythm Therapy, and Collaborative Care (psychoeducation). There are two kinds of treatment pathways in STEP-BD, and participants may have the opportunity to take part in both. The medications and psychosocial interventions provided in these pathways are considered among the best choices of treatment for bipolar disorder in everyday clinical practice. In the Best Practice Pathway, participants are followed by a STEP-BD certified doctor and all treatment choices are individualized. Everyone enrolled in STEP-BD may participate in this pathway. Participants and their doctors work together to decide on the best treatment plans and to change these plans if needed. Also, anyone who wishes to stay on his or her current treatment upon entering STEP-BD may do so in this pathway. Adolescents and adults age 15 years and older may participate in the Best Practice Pathway. For adults age 18 and older, another way to participate is in the STEP-BD Randomized Care Pathways. Depending on their symptoms, participants may be offered treatment in one or more of these pathways during the course of the study. The participants remain on mood-stabilizing medication. However, because doctors are uncertain which of several treatment strategies work best for bipolar disorder, another medication and/or talk therapy may be added. Each Randomized Care Pathway involves a different set of these additional treatments. Unlike in the Best Practice Pathway, the participants in the Randomized Care Pathways are randomly assigned to treatments. Also, in some cases, neither the participant nor the doctor will be told which of the different medications is being added. This is called a double-blind study and is done so that the medication effects can be evaluated objectively, without any unintended bias that may come from knowing what has been assigned. Participants will not be assigned medications that they have had bad reactions to in the past, that they are strongly opposed to, or that the doctor feels are unsuitable for them. The medication(s) participants may be randomly assigned to in the Randomized Care Pathways are free of charge. There are other treatment options for participants if they do not respond well to the treatment assigned to them. Also, participants may return to the Best Practice Pathway at any time. About 1,500 individuals will be enrolled in at least one Randomized Care Pathway during their period of participation in STEP-BD. It is important to note that STEP-BD provides continuity of care. For example, if a participant starts out in the Best Practice Pathway and later chooses to enter one of the Randomized Care Pathways, he or she continues with the same STEP-BD doctor and treatment team. Then, after completing the Randomized Care Pathway, the participant may return to the Best Practice Pathway for ongoing, individually-tailored treatment. Follow the link to view study info at Clinicaltrials.gov, http://www.clinicaltrials.gov/ct/show/NCT00012558?order=1

• Resource
• SciCrunch
• 15 years ago - by Anonymous

This is the second in a series of modules on neuroscience and psychiatry. This module describes neuroscience research on animal models of fear that informed human studies of fear/safety, anxiety and anxiety disorders. This model helps shed light on the symptoms of PTSD and lead to the development of a novel treatment that has been successful in research studies for several anxiety disorders.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

This comprehensive free collection of multimedia resources and inquiry-based activities tied to the National Science Education Standards help teachers and students learn about the structure, function and cognitive aspects of the human brain. The packet includes a teacher's manual, student manual, DVD of videos, and a CDROM of accompanying materials.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Blog by the NIMH Director, Thomas R. Insel, M.D. Users may sort posts by topic and/or subsribe to the RSS Feed, http://www.nimh.nih.gov/site-info/feed-directors-blog.atom

• Resource
• SciCrunch
• 15 years ago - by Anonymous

The mission of the Spinal Muscular Atrophy Foundation is to accelerate the development of a treatment for SMA, the number one genetic killer of infants and toddlers. To help speed the realization of a treatment or cure, the SMA Foundation is committed to: Developing private sector involvement in SMA drug development by fostering alliances between academia, government, and pharmaceutical and biotechnology companies Increasing government funding and support through targeted efforts to increase Congressional and NIH awareness Raising awareness of SMA among government leaders, members of the pharmaceutical and biotechnology industries, and the public at large

• Resource
• SciCrunch
• 16 years ago - by Anonymous

Dataset from an investigation of biochemical evidence of myocardial strain, oxidative stress, and cardiomyocyte injury in 55 acute KD subjects (30 with paired convalescent samples), 54 febrile control (FC), and 50 healthy control (HC) children by measuring concentrations of cardiovascular biomarkers. NT-proBNP and sST2 were elevated in acute KD subjects and correlated with impaired myocardial relaxation. These findings, combined with elevated levels of cTnI, suggest that both cardiomyocyte stress and cell death are associated with myocardial inflammation in acute KD.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Software programs that are extensions of the LINKAGE programs that allow the disease phenotype to be under the control of disease two loci. (entry from Genetic Analysis Software)

• Resource
• SciCrunch
• 14 years ago - by Anonymous

Brain tissue donation program at the UT Southwestern Memory Clinic that aims to utilize these contributions for research on Alzheimer's. Diagnosis of Alzheimer's disease or other dementias are made through autopsy, the results of which are available to family members.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

A center dedicated to discovering treatments and providing preventative measures for Alzheimer's Disease. Research is strongly focused on brain changes in regards to healthy aging, mild cognitive impairment and other disorders, such as dementia. It aims to improve diagnostic measures and care giving techniques, discover more effective medical interventions, and understand the etiology of the disease and find an eventual cure. The center provides diagnostic evaluations of adult memory problems, as well as the opportunity to participate in clinical research to aid in finding better Alzheimer's treatments.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

The Committee on Publication Ethics (COPE) was established in 1997 by a small group of medical journal editors in the UK but now has over 7000 members worldwide from all academic fields. Membership is open to editors of academic journals and others interested in publication ethics. Several major publishers (including Elsevier, WileyBlackwell, Springer, Taylor & Francis, Palgrave Macmillan and Wolters Kluwer) have signed up their journals as COPE members. COPE provides advice to editors and publishers on all aspects of publication ethics and, in particular, how to handle cases of research and publication misconduct. It also provides a forum for its members to discuss individual cases (meeting four times a year in the UK and once a year in North America). COPE does not investigate individual cases but encourages editors to ensure that cases are investigated by the appropriate authorities (usually a research institution or employer). All COPE members are expected to follow the Code of Conduct for Journal Editors. COPE will investigate complaints that members have not followed the Code. COPE also funds research on publication ethics, publishes a quarterly newsletter and organises annual seminars in the UK and the USA. COPE has also created an audit tool for members to measure compliance with its Code of Conduct and Best Practice Guidelines for Journal Editors. What guidance is available on this website (for members and non-members)? * COPE Code of Conduct and Best Practice Guidelines for Journal Editors * Flowcharts on how to handle common ethical problems * Other COPE guidelines (eg on retractions) * Sample letters (to adapt for use) * Database of all cases discussed at COPE Forum (including podcasts of the discussion (where available), the advice given and the outcome of cases) Benefits of COPE membership COPE members can: * receive advice on individual cases via the Forum * access the eLearning package (due Q2 2011) * use the ethical audit tool to see how well their journals match COPE''s guidelines * use the COPE logo in their journal * apply for COPE research grants * stand for election to COPE Council

• Resource
• SciCrunch
• 15 years ago - by Anonymous

THIS RESOURCE IS NO LONGER IN SERVCE, documented September 2, 2016. Service that determines the Suspected Overlap Among OBO Foundry Candidate Ontologies.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Laser tool that enables neurons to be optically silenced by pulses of yellow light, the light-activated chloride pump halorhodopsin (Halo), in a paper entitled Multiple-color optical activation, silencing, and desynchronization of neural activity, with single-spike temporal resolution. Temporally precise, noninvasive control of activity in well-defined neuronal populations is a long-sought goal of systems neuroscience. We adapted for this purpose the naturally occurring algal protein Channelrhodopsin-2, a rapidly gated light-sensitive cation channel, by using lentiviral gene delivery in combination with high-speed optical switching to photostimulate mammalian neurons. We demonstrate reliable, millisecond-timescale control of neuronal spiking, as well as control of excitatory and inhibitory synaptic transmission. This technology allows the use of light to alter neural processing at the level of single spikes and synaptic events, yielding a widely applicable tool for neuroscientists and biomedical engineers. The quest to determine how precise neural activity patterns mediate computation, behavior, and pathology would be greatly aided by a set of tools for reliably activating and inactivating genetically targeted neurons, in a temporally precise and rapidly reversible fashion. Having earlier adapted a light-activated cation channel, 1channelrhodopsin-2 (ChR2), for allowing neurons to be stimulated by blue light, we searched for a complementary tool that would enable optical neuronal inhibition, driven by light of a second color. Here we report that targeting the 1codon-optimized form of the light-driven chloride pump halorhodopsin from the archaebacterium Natronomas pharaonis (hereafter abbreviated Halo) to genetically-specified neurons enables them to be silenced reliably, and reversibly, by millisecond-timescale pulses of yellow light. We show that trains of yellow and blue light pulses can drive high-fidelity sequences of hyperpolarizations and depolarizations in neurons simultaneously expressing yellow light-driven Halo and blue light-driven ChR2, allowing for the first time manipulations of neural synchrony without perturbation of other parameters such as spiking rates. The Halo/ChR2 system thus constitutes a powerful toolbox for multichannel photoinhibition and photostimulation of virally or transgenically targeted neural circuits without need for exogenous chemicals, enabling systematic analysis and engineering of the brain, and quantitative bioengineering of excitable cells.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

Provides relevant and curated health news and articles specifically tailored to individual interests. Content is curated from sources such as JAMA, BMJ, BMA and more that are archived in an easy-to-search manner. The portal contains video content that is created in partnership with Healthology, a network of holistic care clinics, to bring informative videos to the public on a regular basis. The site also provides a platform to interact with fellow readers through forums, weekly newsletters and notifications when relevant content is added to categories of interest.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

A multi-site, clinical research study examining treatment options for teens whose depression has not improved after one adequate trial of a selective serotonin reuptake inhibitor (SSRI), a type of antidepressant. The purpose of the study is to determine how best to treat adolescents with depression that is resistant to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy. The TORDIA study aims to develop useful clinical guidelines for the care and management of adolescent depression. Adolescents ages 12 to 18, currently taking a prescribed selective serotonin reuptake inhibitor (SSRI) and still experiencing depression, participate in a 12-week randomized treatment study that includes one of four conditions: (1) switching to an alternative SSRI, (2) switching to a different non-SSRI antidepressant, (3) switching to an alternative SSRI and receiving cognitive behavioral therapy (CBT), or (4) switching to a different non-SSRI antidepressant and receiving CBT. This is a double-blind study, which means that neither the participant nor the clinical staff will know which of the three possible medications has been assigned. Participants who respond to the assigned treatment will receive 12 additional weeks of the same treatment. Those who do not appear to be getting better will be offered 12 weeks of an alternative, individualized treatment plan based on each participant''s particular needs. All participants will receive follow-up psychiatric evaluations for 12 months after the 12-week continuation phase of the study, regardless of treatment adherence. For more information visit, http://www.clinicaltrials.gov/ct2/show/NCT00018902?term=clinical+trial+AND+treatment+of+ssri-resistant+AND+depression+AND+TORDIA+AND+study&rank=1

• Resource
• SciCrunch
• 15 years ago - by Anonymous

A blog focusing on the function of adult neurogenesis in the dentate gyrus of the hippocampus, including discussion of scientific research papers, methods and protocols, and other trends or observations about the field.

• Resource
• SciCrunch
• 15 years ago - by Anonymous

A network that provides support and NIH funding for neuroscience research and drug development through access to contract research organizations for outsourcing and research consultation. Successful applicants will receive funding to conduct biological testing, access to a full range of industry-style drug development services and expertise, and control of the intellectual property for drug candidates. Funded projects include treatments for age-related macular degeneration, ALS, Alzheimer's disease, depression, hearing loss, optic neuropathy and stroke.

• Resource
• SciCrunch
• 15 years ago - by Anonymous